Abstract: Objective To summarize the research progress in adverse reactions associated with obinutuzumab used to treat follicular lymphoma (FL), and provide data for optimizing therapeutic regimens and mitigating the risks of adverse reactions. Methods Based on literature analysis, the structure, properties, types of adverse reactions, real-world data, and mechanisms of obinutuzumab were analyzed. Results As a glycoengineered type II humanized anti-CD20 monoclonal antibody, obinutuzumab demonstrated good efficacy and antitumor activity in B-cell malignancies. However, its clinical use might be associated with such adverse reactions as infusion-related reactions (IRR), increased risk of infection, tumor lysis syndrome (TLS), myelosuppression, hepatitis B virus (HBV) reactivation, and progressive multifocal leukoencephalopathy (PML), involving such factors as activation of the immune system, cytokine release, B-cell depletion, and impaired immune surveillance. Conclusion Obinutuzumab has shown significant efficacy in the treatment of FL. However, its potential adverse reactions deserve attention. Subsequent studies need to find out more about the mechanisms behind these adverse reactions and develop effective prevention and management strategies to optimize treatment regimens and reduce the risk of adverse reactions.

Key words: Obinutuzumab, Follicular Lymphoma, Anti-CD20 Monoclonal Antibody, Adverse Drug Reactions, Mechanism Research